What are the progression‑free survival and overall survival outcomes when bevacizumab and olaparib are added to adjuvant carboplatin‑paclitaxel chemotherapy in patients with advanced (stage III–IV) high‑grade serous ovarian carcinoma?

Progression-Free Survival and Overall Survival with Bevacizumab Plus Olaparib Maintenance in Advanced High-Grade Serous Ovarian Cancer

In patients with newly diagnosed advanced (stage III-IV) high-grade serous ovarian cancer who have HRD-positive tumors, adding maintenance olaparib to bevacizumab after first-line platinum-based chemotherapy provides a median PFS of 37.2 months and a 5-year OS of 65.5%, compared to 17.7 months PFS and 48.4% 5-year OS with bevacizumab alone. 1, 2

Key Survival Outcomes by Biomarker Status

HRD-Positive Patients (Including BRCA Mutations)

The most clinically meaningful benefits occur in patients with homologous recombination deficiency:

• Median PFS: 37.2 months (olaparib + bevacizumab) vs 17.7 months (bevacizumab alone)
• Hazard ratio for PFS: 0.33 (95% CI: 0.25-0.45) 3
• 5-year PFS rate: 46% vs 21% 1
• Median OS: 75.2 months vs 57.3 months
• Hazard ratio for OS: 0.62 (95% CI: 0.45-0.85) 1
• 5-year OS rate: 65.5% vs 48.4% 2

BRCA-Mutated Subgroup (Germline or Somatic)

This subgroup demonstrates the greatest survival benefit:

• Median PFS: Not reached in initial analysis, with sustained benefit at extended follow-up 3
• Hazard ratio for OS: 0.60 (95% CI: 0.39-0.93) 1
• 3-year freedom from progression: Substantially higher than placebo groups 1

HRD-Positive Without BRCA Mutations

Significant benefit persists even without BRCA mutations:

• Median PFS: 28.1 months vs 16.6 months
• Hazard ratio for PFS: 0.43 (95% CI: 0.28-0.66) 3
• Hazard ratio for OS: 0.71 (95% CI: 0.45-1.13) 1

Survival Outcomes by Clinical Risk Stratification

Higher-Risk Patients

Defined as stage III with residual disease after upfront surgery or neoadjuvant chemotherapy, or stage IV disease (74% of patients):

• Hazard ratio for PFS: 0.46 (95% CI: 0.34-0.61) in HRD-positive patients 2
• 5-year PFS: 35% (olaparib + bevacizumab) vs 15% (bevacizumab alone) 2
• Hazard ratio for OS: 0.70 (95% CI: 0.50-1.00) 2
• 5-year OS: 55% vs 42% 2

Lower-Risk Patients

Defined as stage III with no residual disease after upfront surgery (26% of patients):

• Hazard ratio for PFS: 0.26 (95% CI: 0.15-0.45) in HRD-positive patients 2
• 5-year PFS: 72% (olaparib + bevacizumab) vs 28% (bevacizumab alone) 2
• 24-month PFS: 90% vs 43% 4
• Hazard ratio for OS: 0.31 (95% CI: 0.14-0.66) 2
• 5-year OS: 88% vs 61% 2

The lower-risk HRD-positive subgroup shows an 85% reduction in risk of progression or death, representing exceptional long-term remission potential 4.

HRD-Negative Patients

No survival benefit was observed in patients with HRD-negative tumors regardless of clinical risk. 1, 2 The PAOLA-1 trial demonstrated no statistically significant improvement in PFS or OS in this population, making olaparib addition inappropriate for HRD-negative disease.

Secondary Endpoints

Progression-Free Survival 2 (PFS2)

After median follow-up of 35.5 months:

• Median PFS2: 36.5 months (olaparib + bevacizumab) vs 32.6 months (bevacizumab alone)
• Hazard ratio: 0.78 (95% CI: 0.64-0.95; P = 0.0125) 5

Time to Second Subsequent Therapy

• Median time: 38.2 months vs 31.5 months
• Hazard ratio: 0.78 (95% CI: 0.64-0.95; P = 0.0115) 5

Critical Treatment Considerations

Guideline-Based Recommendations

The ASCO 2020 guidelines strongly recommend olaparib plus bevacizumab maintenance for patients with stage III-IV high-grade serous or endometrioid ovarian cancer who have germline or somatic BRCA1/2 mutations and/or genomic instability (HRD-positive by Myriad myChoice CDx) and achieve CR/PR to chemotherapy plus bevacizumab 6.

The NCCN 2024 guidelines emphasize that while no statistically significant OS improvement was seen in the intent-to-treat population, clinically meaningful OS benefit occurred specifically in HRD-positive tumors 1.

Treatment Duration

• Olaparib: 300 mg orally twice daily for up to 24 months 6, 3
• Bevacizumab: 15 mg/kg every 3 weeks for up to 15 months total (including treatment phase) 6, 3

Common Pitfalls to Avoid

1. Do not use this combination in HRD-negative patients - no benefit demonstrated and exposes patients to unnecessary toxicity 1, 2

2. Do not restrict treatment to higher-risk patients only - lower-risk HRD-positive patients derive substantial, potentially curative benefit with 88% 5-year OS 2

3. Ensure HRD testing is performed - treatment decisions critically depend on biomarker status; use validated assays like Myriad myChoice CDx 6

4. Account for crossover effects - approximately 27% of patients in placebo arms received PARP inhibitors as subsequent therapy, which may dilute OS differences 5

The evidence strongly supports that biomarker-driven patient selection is essential - HRD status, not clinical risk alone, determines who benefits from this combination therapy 1, 2, 7.